Efficacy and safety of flexible-dose oral sildenafil citrate (Viagra((R))) in the treatment of erectile dysfunction in Brazilian and Mexican men

A 12-week, double-blind, placebo-controlled, multicenter study evaluated the efficacy and safety of flexible-dose sildenafil citrate (Viagra((R))) treatment (25, 50 or 100 mg) in Brazilian and Mexican men with erectile dysfunction (ED) of broad-spectrum etiology. Efficacy was assessed on the basis of responses to the 15-item International Index of Erectile Function (IIEF) questionnaire, completed at baseline and after 12 weeks of treatment. At end point, mean scores for all IIEF domains of sexual function (erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction) were significantly (P < 0.0001) higher in the sildenafil group (n = 109) than in the placebo group (n = 105). These findings confirm the significant increases in frequency of penetration and frequency of maintained erections reported previously. Sildenafil treatment was well tolerated. the most common adverse events were headache and flushing. in conclusion, sildenafil is a well-tolerated and effective treatment for ED of broad-spectrum etiology in Latin American men.Hosp Albert Einstein, BR-01250000 São Paulo, BrazilTorre Hosp Angeles del Pedregal, Consultorio 827, MexicoFac Ciencias Med Santa Casa, Porto Alegre, RS, BrazilHosp Clin Cuiritiba, Curitiba, Parana, BrazilUniv Estadual Campinas, Fac Ciencias Med, Campinas, SP, BrazilClin Rio Claro, Rio Claro, SP, BrazilUniv Estadual Rio de Janeiro, Fac Med, Rio de Janeiro, BrazilUniversidade Federal de São Paulo, Escola Paulista Med, São Paulo, BrazilHosp Servidor Publ Estadual, São Paulo, BrazilUniversidade Federal de São Paulo, Escola Paulista Med, São Paulo, BrazilWeb of Scienc

Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction

The aim of this study was to evaluate the efficacy and safety of oral sildenafil to treat erectile dysfunction (ED) in chronic renal failure in patients on hemodialysis (HD). A double-blind, randomized, placebo-controlled study of oral sildenafil (50 mg) administered as required in HD patients with ED was designed. Patients on HD for at least 6 mo and who had a stable relationship with a female sexual partner were included. Patients older than 70 yr with penile anatomic abnormalities, cirrhosis, diabetes, angina, severe anemia, and those who were on nitrate treatment or with a recent history of stroke or myocardial infarction were not included. The International Index of Erectile Dysfunction (IIEF) was employed to evaluate ED and treatment response. Forty-one patients were evaluated (21 received placebo, and 20 sildenafil). Baseline clinical and demographic parameters were similar in both groups. Sildenafil was associated with improvement in the score of all questions and domains of the IIEF, except those related to sexual desire. Using the erectile function domain to evaluate primary efficacy, improvement was observed in 85% of the sildenafil patients compared with 9.5% of placebo patients. Sildenafil use resulted in normal EF scores in 35% of sildenafil patients. Sildenafil was well tolerated. Headaches and flushing occurred in both groups. Dyspepsia was reported by two patients in the sildenafil group. In conclusion, oral sildenafil seems to be an effective and safe treatment for ED in selected patients with chronic renal failure on hemodialysis

Efeitos do alopurinol sobre a lipoperoxidação de membranas celulares renais na síndrome da isquemia e reperfusão : estudo experimental em ratos

Objetivo: Vários estudos têm demonstrado que Radicais Livres de Oxigênio (RLO) contribuem para o dano celular decorrente da isquemia e reperfusão. Este estudo foi desenvolvido como o objetivo de avaliar os efeitos da isquemia e reperfusão renal em ratos, tratados ou não com alopurinol, sobre a lipoperoxidação (LPO) das membranas celulares renais. Método: Foram usados ratos Wistar distribuídos em 4 grupos e submetidos a períodos de isquemia e reperfusão renal ou não, dependendo do grupo. Também foram submetidos ou não a tratamento com alopurinol na dose de 50 e 150 mg/Kg por via intraperitoneal, 5 e 1 horas antes do procedimento. Na avaliação da lipoperoxidação utilizou-se os métodos do TBARS e QL.Resultados: Os resultados demonstraram aumento da LPO nos animais submetidos a isquemia e reperfusão renal. No entanto, estes efeitos deletérios foram reduzidos com o pré-tratamento com alopurinol (p<0,05). Conclusão: O dano causado em animais submetidos a isquemia e reperfusão renal pode ser demonstrado e quantificado pela LPO. Além disso, o alopurinol demonstrou proteção renal contra o dano decorrente desta síndrome, diminuindo a LPO nestes animais. Estes resultados sugerem que a via da xantina oxidase é uma das mais importantes rotas metabólicas envolvidas na geração de RLO, estes responsáveis em parte pelos danos funcionais do rim na síndrome da isquemia e reperfusão deste órgão.Background:Evidence has accumulated that oxygen free radical (OFR) contribute to the cellular damage induced by ischemiareperfusion. This study was undertaken to determine the effects of renal ischemia-reperfusion in rats, treated or not with allopurinol evaluating the lipid peroxidation (LPO) of renal cellular membranes. Method: Wistar rats were divided into 4 groups (n=10) and submitted to 50 minutes of renal ischemia and reperfusion and treated or not with allopurinol (50 and 150 mg/Kg of body, 5 and 1 hour before ischemia, respectively). The lipid peroxidation was assessed by TBARS method (Thiobarbituric acid reactives substances) and CL method (Chemiluminescence). Results:The results showed that animals submitted to renal ischemia-reperfusion had renal LPO damage. These effects of ischemia and reperfusion were reduced by treatment with allopurinol (p<0,05). Conclusion: These results suggest that xanthine oxidase is one of the most important pathway envolved in the generation of OFR and chemical reactives elements with injury potencial at the renal cellular membranes due to ischemia-reperfusion syndrome. At least, allopurinol showed benefical effects preventing damage due to renal ischemiareperfusion injury